U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06795009) titled 'Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer' on Jan. 23.
Brief Summary: The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
Study Start Date: May 31, 2025
Study Type: INTERVENTIONAL
Condition:
Uterine Cancer
Endometrial Cancer
Intervention:
DRUG: Zanzalintinib
Taken by mouth.
DRUG: Paclitaxel
175 mg^m2 intravenous over 3 hours.
Recruitment Status: NOT_YET_RECRUITING
S...